trichomonas vaginalis

Metronidazole (Metronidazol) is a synthetic nitroimidazole derivative with antiprotozoal and antibacterial activities.

SQ109 (NSC-722041) is an effective inhibitor of the trypomastigote form of the parasite (IC50 = 50 nM). SQ109 is an antitubercular agent and targets MmpL3.

RR-11a analog (aza-peptide Michael acceptor, 7a) is an inhibitor of asparaginyl endopeptidase with IC50s of 4.5 nM, 4.5 nM and 31 nM for AE1 in Trichomonas Vaginalis, AE in Ixodes ricinus and AE in Schistosoma mansoni, respectively.

Sulnidazole, a nitroimidazole derivative, functions as an antiprotozoal compound effective against Trichomonas vaginalis.

Stirimazole, an imidazole derivative, has demonstrated the ability to inhibit Trichomonas vaginalis in vitro at an effective concentration of 0.225 μg ml. In animal studies, an oral dose of 20 mg kg successfully eradicated infectious lesions in mice.

Fexinidazole (HOE 239) is an antiparasitic agent with activity against Trypanosoma cruzi, Tritrichomonas foetus, Trichomonas vaginalis, Entamoeba histolytica, Trypanosoma brucei, and Leishmania donovani. The biologically relevant active metabolites in vivo are the sulfoxide and sulfone.

LL-37 FK-13 TFA, the TFA salt form of LL-37 FK-13, is an antimicrobial agent that inhibits Trichomonas vaginalis. It exhibits minimal hemolytic effects on human red blood cells and shows slight cytotoxicity towards human fibroblasts.